Published in Retrovirology on December 20, 2010
Recombinant origin of the retrovirus XMRV. Science (2011) 3.54
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome. J Virol (2011) 1.73
DNA extraction columns contaminated with murine sequences. PLoS One (2011) 1.55
Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology (2010) 1.49
Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology (2011) 1.42
The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion (2011) 1.41
PCR master mixes harbour murine DNA sequences. Caveat emptor! PLoS One (2011) 1.41
In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS One (2012) 1.33
Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. J Virol (2011) 1.28
Phylogenetic analysis of murine leukemia virus sequences from longitudinally sampled chronic fatigue syndrome patients suggests PCR contamination rather than viral evolution. J Virol (2011) 1.23
Gammaretroviral integration into nucleosomal target DNA in vivo. J Virol (2011) 1.23
No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology (2011) 1.22
Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines. PLoS One (2011) 1.22
No association of xenotropic murine leukemia virus-related viruses with prostate cancer. PLoS One (2011) 1.19
Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells. J Virol (2011) 1.18
No evidence of XMRV in prostate cancer cohorts in the Midwestern United States. Retrovirology (2011) 1.18
Multiple sources of contamination in samples from patients reported to have XMRV infection. PLoS One (2012) 1.08
XMRV and prostate cancer--a 'final' perspective. Nat Rev Urol (2012) 1.08
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther (2011) 1.06
No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort. PLoS One (2011) 1.04
Recombinant origin, contamination, and de-discovery of XMRV. Curr Opin Virol (2012) 0.96
Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV. Front Oncol (2013) 0.95
Human saliva as route of inter-human infection for mouse mammary tumor virus. Oncotarget (2015) 0.94
Characterization, mapping, and distribution of the two XMRV parental proviruses. J Virol (2011) 0.93
Restricted replication of xenotropic murine leukemia virus-related virus in pigtailed macaques. J Virol (2012) 0.93
No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. PLoS One (2011) 0.89
Open access, moving to the fore. Retrovirology (2012) 0.88
XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1). Prostate (2011) 0.87
Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples. Adv Virol (2011) 0.87
Conference highlights of the 15th International Conference on Human Retrovirology: HTLV and related retroviruses, 4-8 June 2011, Leuven, Gembloux, Belgium. Retrovirology (2011) 0.87
Absence of XMRV and closely related viruses in primary prostate cancer tissues used to derive the XMRV-infected cell line 22Rv1. PLoS One (2012) 0.87
No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome. PLoS One (2011) 0.85
Murine gammaretrovirus group G3 was not found in Swedish patients with myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. PLoS One (2011) 0.84
No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses. PLoS One (2012) 0.83
Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer. Adv Virol (2011) 0.83
Detection of murine leukemia virus or mouse DNA in commercial RT-PCR reagents and human DNAs. PLoS One (2011) 0.83
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. Nucleic Acids Res (2011) 0.82
Endogenous Murine Leukemia Viruses: Relationship to XMRV and Related Sequences Detected in Human DNA Samples. Adv Virol (2011) 0.82
The "infectious" nature of human prostate cancer: a cautionary note. Oncotarget (2011) 0.82
Failure to Detect XMRV-Specific Antibodies in the Plasma of CFS Patients Using Highly Sensitive Chemiluminescence Immunoassays. Adv Virol (2011) 0.82
Sensitivity of PCR assays for murine gammaretroviruses and mouse contamination in human blood samples. PLoS One (2012) 0.82
No evidence of murine leukemia virus-related viruses in live attenuated human vaccines. PLoS One (2011) 0.82
No Evidence of XMRV or MuLV Sequences in Prostate Cancer, Diffuse Large B-Cell Lymphoma, or the UK Blood Donor Population. Adv Virol (2011) 0.82
Lack of Detection of Xenotropic Murine Leukemia Virus-Related Virus in HIV-1 Lymphoma Patients. Adv Virol (2011) 0.81
Naturally Occurring Polymorphisms of the Mouse Gammaretrovirus Receptors CAT-1 and XPR1 Alter Virus Tropism and Pathogenicity. Adv Virol (2011) 0.80
Absence of XMRV in peripheral blood mononuclear cells of ARV-treatment naïve HIV-1 infected and HIV-1/HCV coinfected individuals and blood donors. PLoS One (2012) 0.80
No association between XMRV or related gammaretroviruses in Australian prostate cancer patients. Virol J (2013) 0.80
Lack of evidence for retroviral infections formerly related to chronic fatigue in Spanish fibromyalgia patients. Virol J (2013) 0.79
Xenotropic murine leukemia virus-related virus in monozygotic twins discordant for chronic fatigue syndrome. Diagn Microbiol Infect Dis (2011) 0.79
Sexual Transmission of XMRV: A Potential Infection Route. Adv Virol (2011) 0.79
Development of sensitive single-round pol or env RT-PCR assays to screen for XMRV in multiple sample types. J Virol Methods (2011) 0.78
No evidence of xenotropic murine leukemia virus-related virus transmission by blood transfusion from infected rhesus macaques. J Virol (2012) 0.78
Susceptibility of human lymphoid tissue cultured ex vivo to xenotropic murine leukemia virus-related virus (XMRV) infection. PLoS One (2012) 0.78
Prevalence of XMRV nucleic acid and antibody in HIV-1-Infected men and in men at risk for HIV-1 Infection. Adv Virol (2011) 0.78
Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and the Safety of the Blood Supply. Clin Microbiol Rev (2016) 0.77
Generation of multiple replication-competent retroviruses through recombination between PreXMRV-1 and PreXMRV-2. J Virol (2013) 0.77
Intrinsic DNA synthesis fidelity of xenotropic murine leukemia virus-related virus reverse transcriptase. FEBS J (2012) 0.76
XMRV Discovery and Prostate Cancer-Related Research. Adv Virol (2011) 0.76
Absence of detectable XMRV and other MLV-related viruses in healthy blood donors in the United States. PLoS One (2011) 0.76
Is XMRV a causal virus for prostate cancer? Asian J Androl (2011) 0.75
Microbial Community Responses to Increased Water and Organic Matter in the Arid Soils of the McMurdo Dry Valleys, Antarctica. Front Microbiol (2016) 0.75
Testing strategies for detection of xenotropic murine leukemia virus-related virus infection. Adv Virol (2011) 0.75
What can academia learn from XMRV studies? Nat Rev Urol (2012) 0.75
Equal versus equivalent access to the scientific literature. Retrovirology (2011) 0.75
No detection of the retrovirus xenotropic murine leukemia virus-related virus in individuals with hemophilia. Transfus Med Hemother (2013) 0.75
Retracted Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science (2009) 10.76
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Retracted XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A (2009) 6.72
Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One (2010) 4.66
Retracted Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A (2010) 4.31
Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25
Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology (2010) 4.18
Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology (2009) 4.11
Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology (2010) 3.64
Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev (2008) 3.07
XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology (2010) 2.55
Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions. J Infect Dis (2010) 2.12
Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis (2010) 2.05
Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J Virol (2009) 2.00
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
A cautionary tale of virus and disease. BMC Biol (2010) 1.93
Xenotropic murine leukemia virus-related gammaretrovirus in respiratory tract. Emerg Infect Dis (2010) 1.40
Mouse retroviruses and chronic fatigue syndrome: Does X (or P) mark the spot? Proc Natl Acad Sci U S A (2010) 1.09
Expression of intracisternal A-particle retrotransposons in primary tumors of oncogene-expressing transgenic mice. Oncogene (1997) 1.04
Current status of xenotropic murine leukemia virus-related retrovirus in chronic fatigue syndrome and prostate cancer: reach for a scorecard, not a prescription pad. J Infect Dis (2010) 1.01
Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med (2005) 14.59
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
The Oslo definitions for coeliac disease and related terms. Gut (2012) 5.76
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
The effects of whole-vault cranioplasty versus strip craniectomy on long-term neuropsychological outcomes in sagittal craniosynostosis. Plast Reconstr Surg (2014) 5.18
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One (2010) 4.66
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Recombinant origin of the retrovirus XMRV. Science (2011) 3.54
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe (2010) 3.08
The solitary wave of asexual evolution. Proc Natl Acad Sci U S A (2003) 2.97
Effects of retroviruses on host genome function. Annu Rev Genet (2008) 2.96
Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature (2010) 2.91
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Detailed analysis of patients with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institutional study. J Urol (2013) 2.76
Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology (2010) 2.75
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS (2006) 2.71
Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites. Proc Natl Acad Sci U S A (2005) 2.64
Antiretroviral therapy in Africa. BMJ (2004) 2.64
Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis (2009) 2.60
Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis (2002) 2.54
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44
Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol (2010) 2.37
Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses. PLoS Genet (2007) 2.33
Assessment of laparoscopic suturing skills of urology residents: a pan-European study. Eur Urol (2008) 2.30
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol (2008) 2.27
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis (2010) 2.15
So you want to become a plastic surgeon? What you need to do and know to get into a plastic surgery residency. Plast Reconstr Surg (2013) 2.13
Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm. AIDS (2011) 2.10
Thoracic Intercostal Nerve Blocks Reduce Opioid Consumption and Length of Stay in Patients Undergoing Implant-Based Breast Reconstruction. Plast Reconstr Surg (2015) 2.10
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09
K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro (2012) 2.03
Human endogenous retrovirus K solo-LTR formation and insertional polymorphisms: implications for human and viral evolution. Proc Natl Acad Sci U S A (2004) 1.94
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut (2006) 1.92
Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. Proc Natl Acad Sci U S A (2004) 1.91
Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS (2008) 1.91
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc Natl Acad Sci U S A (2006) 1.87
Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest (2003) 1.85
Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J Virol (2005) 1.84
Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem (2004) 1.84
Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med (2009) 1.83
Impact of obesity in patients with urolithiasis and its prognostic usefulness in stone recurrence. J Urol (2007) 1.81
Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology (2011) 1.80
Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A (2005) 1.79
Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol (2007) 1.79
Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut (2010) 1.77
High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc Natl Acad Sci U S A (2009) 1.76
Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol (2008) 1.75
Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol (2003) 1.73
Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res (2007) 1.66
The management of gastric polyps. Gut (2010) 1.65
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int (2012) 1.65
Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr (2007) 1.64
RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol (2005) 1.64
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology (2013) 1.63
Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. J Infect Dis (2010) 1.62
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine (2008) 1.62
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle (2012) 1.56
Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis (2002) 1.56
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
A child with avian influenza A (H5N1) infection. Pediatr Infect Dis J (2005) 1.55
DNA extraction columns contaminated with murine sequences. PLoS One (2011) 1.55
Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog (2009) 1.53
Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res (2010) 1.52
Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proc Natl Acad Sci U S A (2007) 1.51
The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS (2002) 1.50
Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol (2008) 1.50
Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis (2008) 1.46
Relationship between retroviral DNA-integration-site selection and host cell transcription. Proc Natl Acad Sci U S A (2005) 1.45
Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology (2013) 1.45
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A (2011) 1.42
Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol (2005) 1.42
The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion (2011) 1.41
Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun (2004) 1.41
Favorable risk factors in patients with positive surgical margin after robot-assisted radical prostatectomy. Can J Urol (2014) 1.40
Human endogenous retroviral elements as indicators of ectopic recombination events in the primate genome. Genetics (2005) 1.40
Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. J Virol Methods (2010) 1.38